MBMaria Angeles Ballesteros

Maria Angeles Ballesteros

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Angeles Ballesteros has a total of 292 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Systemic mitochondrial DNA kinetics after controlled donation after circulatory determination of death lung transplantation do not reflect donor warm ischemic injury: DACMEDAMPs, a prospective multicenter translational study

    by Irene Bello, Ramon Martí, Aroa Gómez-Brey, Silvana Crowley Carrasco, Maria Jesús Melià, Elena García-Arumí, Javier Pérez Vélez, Maria Deu, Sara Naranjo, Eva Fieira, et al.

  • Open Access

    Primary graft dysfunction after heart transplantation: Prevalence, risk factors, and outcomes. A single-center retrospective analysis

    by Joffrey Eduardo Luján Valencia, Manuel Cobo Belaustegui, Cristina Castrillo Bustamante, Iván Olavarri Miguel, Lucía García-Alcalde, Tito Anderson García Moreno, Jorge Placer Martínez, Natalia Royuela Martínez, Paula Martínez Díaz, Eduardo Miñambres, et al.

  • Clinical evidence of the absence of brain perfusion during thoraco-abdominal normothermic regional perfusion in donation after circulatory determination of death

    by Mario Royo-Villanova, Beatriz Domínguez-Gil, José Moya, María Ángeles Ballesteros, Alejandro Ortín, Enrique Montes-Figueroa, Elisabeth Coll, Alicia Pérez-Blanco, Joaquín Zamarro, Borja Suberviola, et al.


  • Effects of PEEP on ICP in ABI patients and its relationship with etiology

    by Jesús Abelardo Barea-Mendoza, Juan Antonio Llompart-Pou, María Ángeles Ballesteros-Sanz, Luisa Corral-Ansa, Mario Chico-Fernández, Zaira Molina-Collado, Maite Misis del Campo, Cándido Pardo-Rey, Juan Angel Tihista-Jiménez, Carmen Corcobado-Márquez, et al.


  • Impact of lung resections on lung transplant grafts due to size discrepancy

    by Víctor M. Mora-Cuesta, Diego Alejandro Murillo-Brito, Pedro José Argos-Vélez, David Iturbe-Fernández, Sara Naranjo-Gozalo, Laura Sánchez-Moreno, Sandra Tello-Mena, Loreto Berjón-De la Vega, Sheila Izquierdo-Cuervo, Claudia Poo-Fernández, et al.


  • Open Access

    Resuscitation and Initial Management After Moderate-to-Severe Traumatic Brain Injury: Questions for the On-Call Shift

    by Jesús Abelardo Barea-Mendoza, Mario Chico-Fernández, Maria Angeles Ballesteros, Alejandro Caballo Manuel, Ana M. Castaño-Leon, J. J. Egea-Guerrero, Alfonso Lagares, Guillermo Morales-Varas, Jon Pérez-Bárcena, Luis Serviá Goixart, et al.

    Traumatic brain injury (TBI) is a leading cause of disability and mortality globally, stemming from both primary mechanical injuries and subsequent secondary responses. Effective early management of moderate-to-severe TBI is essential to prevent secondary damage and improve patient outcomes. This review provides a comprehensive guide for the resuscitation and stabilization of TBI patients, combining clinical experience with current evidence-based guidelines. Key areas addressed in this study include the identification and classification of severe TBI, intubation strategies, and optimized resuscitation targets to maintain cerebral perfusion. The management of coagulopathy and special considerations for patients with concomitant hemorrhagic shock are discussed in depth, along with recommendations for neurosurgical interventions. This article further explores the role of multimodal neuromonitoring and targeted temperature management to mitigate secondary brain injury. Finally, it discusses end-of-life care in cases of devastating brain injury (DBI). This practical review integrates foundational and recent advances in TBI management to aid in reducing secondary injuries and enhancing long-term recovery, presenting a multidisciplinary approach to support acute care decisions in TBI patients.


  • Open Access

    Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity

    by Sandra Llorente-Pelayo, Pablo Docio, Silvia Arriola, Bernardo A. Lavín-Gómez, María T. García-Unzueta, María Ángeles Ballesteros, María J. Cabero-Pérez, Domingo González-Lamuño

    Purpose: Metabolic bone disease of prematurity (MBDP) remains a significant cause of morbidity in extremely premature newborns. In high-risk patients, suspected diagnosis and subsequent treatment modifications, with limitations in terms of sensitivity and specificity, rely on low phosphorus levels and/or high levels of alkaline phosphatase (ALP). We investigated the potential of fibroblast growth factor-23 (FGF23) as an early marker for MBDP when measured at 3–4 weeks of life in at-risk patients. Methods: A single-center prospective observational non-interventional study including preterm newborns of both sexes, with a gestational age of less than 32 weeks and/or a birth weight of less than 1500 g. In the standard biochemical screening for MBDP performed between 3 and 4 weeks of life within a nutritional profile, the determination of FGF23 was included along with other clinical and metabolic studies. The study was conducted at Marqués de Valdecilla University Hospital in Santander, Spain, from April 2020 to March 2021. Participants provided informed consent. Biochemical analyses were conducted using various platforms, and follow-up evaluations were performed at the discretion of neonatologists. Patients at high risk for MBDP received modifications in treatment accordingly. The sample was descriptively analyzed, presenting measures of central tendency and dispersion for continuous variables, and absolute numbers/percentages for categorical ones. Tests used included t-tests, Mann‒Whitney U tests, chi-square tests, logistic regressions, Pearson correlation, and ROC curve analysis (IBM SPSS Statistics version 19). Significance level: P < 0.05. Results: In the study involving 25 at-risk premature newborns, it was found that 20% (n = 5) were diagnosed with MBDP. Three of these patients (60%) were identified as high-risk based on standard biochemical evaluation at 3–4 weeks of age, while the other two patients (40%) were diagnosed in subsequent weeks. However, in all 5 patients, measurement of FGF23 levels would allow for early identification and optimization of treatment before other markers become altered. Low levels of FGF23 at 3–4 weeks, even with normal phosphorus and ALP levels, indicate the need for modifications in nutritional supplementation. Conclusions: MBDP remains a significant concern in extremely premature newborns. Current diagnostic methods rely on limited biochemical markers. Early detection of low FGF23 levels enables timely interventions, potentially averting demineralization.


  • Open Access

    Traumatic Brain Injury and Acute Kidney Injury—Outcomes and Associated Risk Factors

    by Jesús Abelardo Barea-Mendoza, Mario Chico-Fernández, Manuel Quintana-Díaz, Lluís Serviá-Goixart, Ana Fernández-Cuervo, María Bringas-Bollada, María Ángeles Ballesteros-Sanz, Íker García-Sáez, Jon Pérez-Bárcena, Juan Antonio Llompart-Pou

    Our objective was to analyze the contribution of acute kidney injury (AKI) to the mortality of isolated TBI patients and its associated risk factors. Observational, prospective and multicenter registry (RETRAUCI) methods were used, from March 2015 to December 2019. Isolated TBI was defined as abbreviated injury scale (AIS) ≥ 3 head with no additional score ≥ 3. A comparison of groups was conducted using the Wilcoxon test, chi-square test or Fisher’s exact test, as appropriate. A multiple logistic regression analysis was conducted to analyze associated risk factors in the development of AKI. For the result, overall, 2964 (30.2%) had AIS head ≥ 3 with no other area with AIS ≥ 3. The mean age was 54.7 (SD 19.5) years, 76% were men, and the ground-level falls was 49.1%. The mean ISS was 18.4 (SD 8). The in-hospital mortality was 22.2%. Up to 310 patients (10.6%) developed AKI, which was associated with increased mortality (39% vs. 17%, adjusted OR 2.2). Associated risk factors (odds ratio (OR) (95% confidence interval)) were age (OR 1.02 (1.01–1.02)), hemodynamic instability (OR 2.87 to OR 5.83 (1.79–13.1)), rhabdomyolysis (OR 2.94 (1.69–5.11)), trauma-associated coagulopathy (OR 1.67 (1.05–2.66)) and transfusion of packed red-blood-cell concentrates (OR 1.76 (1.12–2.76)). In conclusion, AKI occurred in 10.6% of isolated TBI patients and was associated with increased mortality.


  • Chronic critical illness after trauma injury: outcomes and experience in a trauma center

    by María Juncal Sánchez-Arguiano, Eduardo Miñambres, Elena Cuenca-Fito, Borja Suberviola, Francisco Javier Burón-Mediavilla, María A. Ballesteros

    To determine the prevalence, risk factors and functional results of chronic critical illness (CCI) in polytrauma patients.Single-center observational retrospective studyICU at a tertiary hospital i...


  • Chronic critical illness in polytrauma. Results of the Spanish trauma in ICU registry

    by María Ángeles Ballesteros, María Juncal Sánchez‐Arguiano, Mario Chico‐Fernández, Jesús Abelardo Barea‐Mendoza, Luis Serviá‐Goixart, Marcelino Sánchez‐Casado, Iker García Sáez, Francisca I. Pino‐Sánchez, Juan Antonio Llompart‐Pou, Eduardo Miñambres

    Purpose: Chronic critical illness after trauma injury has not been fully evaluated, and there is little evidence in this regard. We aim to describe the prevalence and risk factors of chronic critical illness (CCI) in trauma patients admitted to the intensive care unit.Material and Methods: Retrospective observational multicenter study (Spanish Registry of Trauma in ICU (RETRAUCI)). Period March 2015 to December 2019. Trauma patients admitted to the ICU, who survived the first 48 h, were included. Chronic critical illness (CCI) was considered as the need for mechanical ventilation for a period greater than 14 days and/or placement of a tracheostomy. The main outcomes measures were prevalence and risk factors of CCI after trauma.Results: 1290/9213 (14%) patients developed CCI. These patients were older (51.2 ± 19.4 vs 49 ± 18.9); p < .01) and predominantly male (79.9%). They presented a higher proportion of infectious complications (81.3% vs 12.7%; p < .01) and multiple organ dysfunction syndrome (MODS) (27.02% vs 5.19%; p < .01). CCI patients required longer stays in the ICU and had higher ICU and overall in‐hospital mortality. Age, injury severity score, head injury, infectious complications, and development of MODS were independent predictors of CCI.Conclusion: CCI in trauma is a prevalent entity in our series. Early identification could facilitate specific interventions to change the trajectory of this process.